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Background: Palmitoylethanolamide (PEA), an endogenous lipid and a congener of anandamide, possesses a wide
range of effects related to metabolic and cellular homeostasis including anti-inflammatory and neuroprotective
properties.
Methods: In vitro, we studied the ability of macrophages to phagocytose Escherichia coli K1 after stimulation
with increasing doses of PEA. In vivo, wild-type mice were treated with PEA intraperitoneally 12 hours and 30
minutes before infection. Meningoencephalitis or sepsis was induced by intracerebral or intraperitoneal infection
with E. coli K1.
Results: Stimulation of macrophages with PEA for 30 minutes increased the phagocytosis of E. coli K1 without
inducing the release of TNFα or CXCL1. Intracellular killing of E. coli K1 was higher in PEA-stimulated than in
unstimulated peritoneal macrophages and microglial cells. Pre-treatment with PEA significantly increased
survival of mice challenged intracerebrally or intraperitoneally with E. coli K1. This effect was associated with
a decreased production of CXCL1, IL-1β and IL-6 in homogenates of spleen and cerebellum in mice treated
with PEA.
Conclusions: Our observations suggest that these protective effects of PEA in mice can increase the resistance
to bacterial infections without the hazard of collateral damage by excessive stimulation of phagocytes.
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Palmitoylethanolamide (PEA) is an endogenous lipid
that belongs to the family of fatty acid ethanolamines
(FAEs) [1]. Under physiological conditions, PEA exists in
all cells, tissues and body fluids. It exerts a multitude of
physiological functions related to metabolic and cellular
homeostasis. The list of properties of PEA has been
widely extended since its discovery as an antipyretic
compound [2] and, nowadays, PEA is known to act as
an anti-inflammatory [3], analgesic [4], and anticonvul-
sant [5] agent. More recently, PEA has been shown to
exert neuroprotective and anti-inflammatory effects
in vivo, that is in spinal cord and traumatic brain injuries* Correspondence: s.redlich77@web.de
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unless otherwise stated.[6] and in neurodegenerative processes such as Parkin-
son’s [7] or Alzheimer’s disease [8]. For a period of time,
PEA was considered to be a cannabinoid receptor 2
(CB2) agonist [9], because several effects were antago-
nized by the selective CB2 receptor blocker SR144528
[4,10]. Many of its properties have been reported to
be dependent on the peroxisome proliferator-activated
receptor (PPAR)α [7,8,11,12]. PPARα is up-regulated by
PEA in a model of spinal cord injury and causes a de-
crease of the release of interleukins and tumor necrosis
factor-α (TNFα) [7,13]. PEA also appears to act via the
transient receptor potential vanilloid-1 (TRPV1) and the
orphan G-protein coupled receptor GPR55 [14,15].
PEA is abundant in the central nervous system (CNS)
where it is produced by neurons, microglia and astrocytesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ized murine BV-2 microglial cells without affecting other
steps of microglial activation, such as proliferation,
microsphere engulfment, and nitric oxide production
[18]. In earlier studies our group reported a significant
increase of phagocytosis of Streptococcus pneumoniae
R6 and Escherichia coli K1 by primary cultures of
microglial cells after PEA treatment [19]. The PEA-
mediated effect on microglial bacterial uptake was not
accompanied by the concomitant release of proinflam-
matory cyto-/chemokines observed after microglial
activation and known to contribute to neuronal injury
[20]. As microglial cells in the CNS, tissue macro-
phages represent the first line of defense against invad-
ing pathogens. PEA can attenuate lipopolysaccharide
(LPS)-induced inflammatory responses in the murine
macrophage cell line RAW264.7 [21], but there are
no data about PEA effects on pathogen uptake by
macrophages.
Data on PEA as a prophylactic/therapeutic agent in
the management of infections are scarce. In an animal
model, oral pre-treatment with PEA increased the resist-
ance of mice to live group A Streptococcus challenge as
well as to injection of crude preparations of Shigella dys-
enteriae toxin and streptolysin O [22]. In the 1970s, PEA
under the brand name Impulsin was tested in six clinical
trials and demonstrated its potential at reducing the in-
cidence and severity of acute respiratory infections
caused by the influenza virus through a non-specific en-
hancement of the immune response [23-25]. Since then,
no other studies were performed to further investigate
the potential of PEA as a prophylaxis or therapy in the
management of infections.
Here, we aim to study the effect of exogenous PEA on
the phagocytosis of E. coli K1 by murine peritoneal mac-
rophages and the protective effect of PEA as a prophy-
lactic agent in experimental murine sepsis and
meningitis induced by intraperitoneal (ip) or intracere-
bral (ic) infection with E. coli K1.
Material and methods
Preparation of murine peritoneal macrophages
C57/Bl6N mice (eight to twelve weeks old) were anes-
thetized with a mixture of 100 mg/kg ketamine (Medi-
star, Holzwickede, Germany) and 10 mg/kg xylazine
(Riemser, Greifswald, Germany). Peritoneal lavage was
performed with 1 ml sterile PBS using an 18-gauge nee-
dle. The peritoneal lavage fluid was collected in a Falcon
tube. This preparation step was repeated twice. The col-
lected macrophages were centrifuged for 10 minutes at
900 rpm, and the pellet was suspended in DMEM
(Gibco, Karlsruhe, Germany). Cells were counted with a
hemocytometer and plated in 96-well plates at a density
of 70,000 cells/well.Primary mouse microglia cell culture
Primary cultures of microglial cells were prepared from
brains of newborn C57/Bl6N mice (p0-p2). After re-
moval of the meninges, cells were mechanically dis-
rupted, treated with trypsin (Sigma-Aldrich, Taufkirchen,
Germany) for 10 minutes to isolate the cells, afterwards
treated with DNAse (Sigma-Aldrich, Taufkirchen,
Germany), centrifuged for 10 minutes at 900 rpm at 4°C
and suspended in DMEM supplemented with 10% heat-
inactivated fetal calf serum (FCS), 100 U/ml penicillin
and 100 μg/ml streptomycin. Cells were plated at a
density of two brains per T75 culture flask (Corning Co-
star, Wiesbaden, Germany) and incubated at 37°C with
5% CO2. Microglial cells were isolated by shaking 200x/
minute for 30 minutes and plated in 96-well plates at a
density of 50,000 cells/well.
Stimulation of macrophages and microglial cells
Cells were either exposed to 0.1 μg/ml LPS from E. coli
serotype O26:B6 (Sigma-Aldrich, Taufkirchen, Germany)
for 24 hours to induce maximum stimulation, to 0.25
mM palmitic acid (PA, Sigma-Aldrich, Taufkirchen,
Germany), to 20 μM fenofibrate (Tocris Bioscience,
Bristol, United Kingdom) or to increasing concentrations
of PEA (1, 3, 10, 30, 100, 300, 1,000 nM) for 30 minutes
or 1 hour. PEA (molecular mass 299.5 Da) was obtained
from Tocris Bioscience (Bristol, United Kingdom) and
dissolved in 0.01% dimethyl sulfoxide (DMSO) according
to the manufacturer’s instructions. We have previously
shown that 30 minutes of PEA exposure was more ef-
fective at increasing bacterial phagocytosis of microglial
cells than 24 hours of PEA stimulation [19]. A control
group with DMEM containing 0.01% DMSO was in-
cluded in all experiments. After stimulation, superna-
tants were stored at −20°C until measurement of
cytokines and chemokines.
Blocking of PPARα
Cells were exposed 1 hour before the agonists PEA,
fenofibrate and palmitic acid, to the PPARα antagonist
GW6471 (1 μM) (Tocris Bioscience, Bristol, United
Kingdom) for 1 hour to block the PEA target PPARα.
Bacteria
The E. coli strain K1 (serotype O18:K1:H7) originally
isolated from the cerebrospinal fluid (CSF) of a child
with neonatal meningitis (gift of Dr. Gregor Zysk, Insti-
tute of Medical Microbiology, Düsseldorf, Germany) was
used in vitro and in all experimental infections. Bacteria
were grown over night on blood agar plates, harvested
in 0.9% saline and stored at −80°C. Frozen aliquots were
used for the experiments and diluted with saline to the
required bacterial concentration.
Figure 1 Phagocytosis of E. coli K1 by unstimulated and
stimulated macrophages. Macrophages were either unstimulated
(treated with medium containing 0.01% DMSO) or stimulated with
PEA for 30 minutes (n ≥ 8 wells/group from two independent
experiments). Data are given as means ± SD. Data were analyzed
by ANOVA followed by Bonferroni multiple comparisons test
(***P < 0.001, **P < 0.01).
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After stimulation, peritoneal macrophages were ex-
posed to the encapsulated E. coli K1 strain for 90 mi-
nutes with a ratio of approximately 100 bacteria per
phagocyte (6 × 106 colony forming units (CFU)/well).
After co-incubation with bacteria, cells were washed
with PBS and incubated with DMEM containing genta-
micin (final concentration 100 μg/ml; Sigma-Aldrich,
Taufkirchen, Germany) for 1 hour to kill extracellular
bacteria. Thereafter, cells were washed twice with PBS
and lysed with 100 μl of distilled water. The intracellu-
lar bacteria were enumerated by quantitative plating of
serial dilutions on sheep blood agar plates.
Intracellular survival assay
LPS- and PEA-stimulated or unstimulated control
macrophages or microglial cells were incubated with
E. coli K1 for 90 minutes. Thereafter, cells were washed
with PBS and incubated in DMEM containing gentamicin
(100 μg/ml; Sigma-Aldrich, Taufkirchen, Germany)
for up to 5 hours to kill extracellular bacteria. At
different time points (60, 120, 180, 240, 300 minutes),
cells were washed with PBS and lysed with distilled
water. The intracellular bacteria were counted by
quantitative plating of serial dilutions on sheep blood
agar plates.
In vivo experiments
The animal experiments were approved by the Animal
Care Committee of the University Medical Center
Göttingen, Germany, and by the Niedersächsisches
Landesamt für Verbraucherschutz und Lebensmittelsi-
cherheit (LAVES), Braunschweig, Lower Saxony, Germany.
Twelve-week-old C57Bl/6N mice were used in all exper-
iments. Animals were weighed and scored daily (0, no
apparent behavioural abnormality; 1, moderate leth-
argy; 2, severe lethargy; 3, unable to walk; 4, dead).
Animals were treated ip 12 hours and 30 minutes be-
fore infection. The PEA-treated group received 0.1
mg/kg PEA in 250 μl of 0.9% NaCl containing 0.3%
DMSO. The control group was treated with 250 μl of
0.9% NaCl containing 0.3% DMSO (saline-treated
group). In survival experiments, the systemic infection
was induced by ip injection of 1 × 105 CFU E. coli K1/
mouse in 250 μl of 0.9% NaCl. Meningoencephalitis
was induced by injection of 1 × 105 CFU E. coli K1/
mouse in 10 μl of 0.9% NaCl into the right forebrain
close to the meninges. In bacteriological studies, sepsis
and meningoencephalitis were induced by ip or ic in-
jection of 3 × 106 CFU E. coli K1/mouse in 250 μl 0.9%
NaCl or 10 μl 0.9% NaCl, respectively. In survival ex-
periments, animals were monitored over two weeks
after infection. In bacteriological studies, animals were
sacrificed 24 hours after infection. Mice, which lostmore than 20% of their weight or were unable to walk,
were sacrificed immediately.
Tissue preparation
At the end time point, animals were anesthetized with a
mixture of 100 mg/kg ketamine (Medistar, Holzwickede,
Germany) and 10 mg/kg xylazine (Riemser, Greifswald,
Germany), and blood was taken by cardiac puncture, col-
lected in 1.5 ml Eppendorf tubes, stored at 4°C for 30
minutes and then centrifuged at 3,000 g for 10 minutes at
4°C. Serum was stored at −20°C until cyto-/chemokine
measurements. Mice were sacrificed by cervical dislocation.
The spleen and the brain were removed, and the cerebel-
lum was dissected from the brain stem. One half of the
spleen and one half of the cerebellum were homogenized in
500 μl saline. For determination of bacterial concentrations,
ten-fold serial dilutions of homogenates and blood in 0.9%
NaCl were plated on sheep blood agar plates.
Cytokine and chemokine measuring
DuoSet ELISA development kits (R&D Systems, Wiesbaden,
Germany) were used for the cytokine measurements.
CXCL1 (chemokine (C-X-C motif) ligand 1; also called KC
or GROα) and TNFα concentrations were characterized in
the supernatants after macrophage stimulation. CXCL1, IL-
1β, IL-6 and IL-10 levels were determined in homogenates
of spleen and cerebellum. The limit of detection was 15 pg/
ml for CXCL1 and TNFα, and 7.5 pg/ml for IL-1β, IL-6 and
IL-10. The color reaction was quantified at 450 nm on a















































































































Figure 2 Involvement of peroxisome proliferator-activated
receptor (PPAR)α in macrophage stimulation and phagocytosis
of E. coli K1 by palmitoylethanolamide (PEA), fenofibrate and
palmitic acid (PA). Macrophages were incubated with the PPARα
antagonist GW6471 (1 μM) for 1 hour. After incubation, macrophages
were either left unstimulated (treated with medium containing
0.01% DMSO) or stimulated with PEA (300 nM) (a), fenofibrate (20
μM) (b) or palmitic acid (PA) (0.25 mM) (c) for 1 hour (n ≥ 9 wells/
group from two independent experiments). In each experiment,
the number of bacteria ingested by the control group (DMSO)
was considered to be 100%. Phagocytic rates are presented as the
percentage of phagocytosis of the respective control group. Data
are given as medians with interquartile ranges and were analyzed
by Kruskal-Wallis test followed by Dunn’s correction for repeated
testing (***P < 0.001, *P < 0.05).
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Statistical analysis and graphical presentation were per-
formed by GraphPad Prism 5 Software (GraphPad Soft-
ware, San Diego, CA, USA). When data were not normally
distributed, they were expressed as medians with 25%/75%
interquartile ranges (IR) and compared by Kruskal-Wallis
test followed by Dunn’s multiple comparisons test to cor-
rect for repeated testing. Comparisons of individual pairs of
not normally distributed data were performed by Mann–
Whitney U-test.
Normally distributed data were expressed as means ±
standard deviations (SD). ANOVA followed by Bonferroni’s
multiple comparisons test was used to perform compari-
sons among more than two groups. Survival curves were
compared by log-rank test. For all comparisons, P < 0.05
was considered statistically significant.
Results
PEA stimulated the phagocytosis of E. coli K1 by
macrophages
The amounts of ingested E. coli K1 after 30 minutes of
stimulation with increasing doses of PEA are shown in
Figure 1. Unstimulated cells (cells stimulated with DMEM
containing 0.01% DMSO, DMSO group) ingested bacteria
at a low rate (mean ± SD) (96.67 ± 23.38 E. coli K1 CFU/
well). Pre-stimulation of peritoneal macrophages with
different concentrations of PEA for 30 minutes led to an
increase of ingested bacteria in a dose-dependent man-
ner. The highest numbers of phagocytosed bacteria
were observed after pre-stimulation with 100 and 300
nM PEA (P < 0.01 and 0.001 versus DMSO-treated
cells, respectively).
Involvement of PPARα in macrophage stimulation and
phagocytosis by PEA
The numbers of ingested E. coli K1 after one hour of PEA,
fenofibrate and palmitic acid stimulation are shown in
Figure 2. Pre-stimulation of macrophages with PEA, fenofi-
brate and palmitic acid for one hour induced a significant










































































Figure 3 Intracellular survival of E. coli K1 by unstimulated,
palmitoylethanolamide (PEA)- and lipopolysaccharide (LPS)-
stimulated microglial cells (a) and macrophages (b). Intracellular
survival was expressed as the number of bacteria (median) recovered at
the different time points (n≥ 9 wells/group from two independent
experiments (a), n ≥ 12 wells/group from two independent
experiments (b)). For statistical comparisons the median number
of bacteria at zero hours was calculated. Then, the number of
bacteria at five hours of each individual well was subtracted from
the median number at zero hours, and these differences were
compared by Kruskall-Wallis Test followed by Dunn’s correction
for repeated testing (***P < 0.001, *P < 0.05).
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treated cells). After blocking with the PPARα antagonist
GW6471 the amounts of ingested E. coli K1 were signifi-
cantly decreased in the fenofibrate and palmitic acid stimu-
lated group (P < 0.05, respectively). GW6471 also tended to
reduce the number of phagocytosed bacteria by PEA-
stimulated cells, the difference, however, failed to reach
statistical significance.
PEA enhanced intracellular killing of E. coli K1 by
microglial cells and macrophages
Stimulation of microglia with LPS and PEA resulted in
a significantly higher number of intracellularly killed E.
coli in comparison to unstimulated cells (P < 0.001, P <
0.05, respectively) (Figure 3a). The median absolute
numbers of intracellularly killed bacteria after 5 hours
were 3,000 CFU/well in LPS-treated and 496 CFU/well
in PEA-treated groups compared to 293 CFU/well in
unstimulated cells.
Pre-stimulation with LPS and PEA induced a higher
number of intracellularly killed bacteria by peritoneal
macrophages (Figure 3b). The absolute numbers of
killed bacteria (medians) were 15,100 CFU/well in LPS-
and 1,990 CFU/well in PEA-treated groups compared to
730 CFU/well in unstimulated macrophages (P < 0.001,
P < 0 .05, respectively).
Prophylaxis with PEA conferred protection against E. coli
K1 infection
Two ip injections of 0.1 mg/kg PEA protected mice
against ip infection with E. coli K1 (Figure 4a). Sur-
vival at 14 days after infection was 77% (30/39) in
PEA-treated mice versus 56% (22/39) in saline-treated
mice (P = 0.042; log-rank test). Two doses of 0.1 mg/
kg of PEA increased the survival of mice infected
ic with E. coli K1 (Figure 4b). Survival at 14 days
after infection was 66% (19/29) in PEA-treated mice
versus 46% (13/28) in saline-treated mice (P = 0.039;
log-rank test).
Bacterial concentrations in spleen, blood and cerebellum
after intracerebral infection
PEA-treated and saline-treated mice were sacrificed 24
hours after ic infection. The bacterial concentration in
blood of PEA-treated mice was below the limit of detection
in 9 of 10 mice (median below the detection limit)
compared to 1 × 103 (1 × 102/6.5 × 103 CFU/ml) in
buffer- treated mice (P = 0.0001; Mann–Whitney U-
test) (Figure 5a). The bacterial density in cerebellum
of PEA-treated mice was 1.6 × 103 (1.2 × 102/7.7 × 103
CFU/ml) compared to 4 × 104 (2 × 104/2 × 105 CFU/ml)
in saline-treated mice (P = 0.0001; Mann–Whitney U-
test) (Figure 5b). Bacterial concentrations in spleen
homogenates of PEA-treated mice was 2 × 101 (belowthe detection limit/4.7 × 102 CFU/ml) compared to 9 × 102
(4 × 102/1 × 104 CFU/ml) in saline-treated mice (P = 0.0003;
Mann–Whitney U-test) (Figure 5c).







































Figure 4 Prophylaxis with palmitoylethanolamide (PEA)
conferred protection against E. coli K1 infection. Kaplan-Meier
survival curves of mice pre-treated intraperitoneally with 0.1 mg/kg
PEA (250 μl, containing 0.3% DMSO in 0.9% NaCl) 12 hours and 30
minutes before infection (n = 39) and control mice (n = 39) (250 μl,
0.3% DMSO in 0.9% NaCl) after ip infection with E. coli K1 (a) and of
mice pre-treated with 0.1 mg/kg PEA (250 μl containing 0.3% DMSO
in 0.9% NaCl) 12 hours and 30 minutes before infection (n = 29)
and control mice (250 μl 0.3% DMSO in 0.9% NaCl) (n = 28) after
intracerebral infection with E. coli K1 (b). The respective groups























































































Figure 5 Bacterial concentrations in spleen, blood and
cerebellum after intracerebral infection. Bacterial concentrations
(CFU/ml) in blood (a), cerebellum (b) and spleen (c) 24 hours after
intracerebral E. coli infection. Statistical analysis was performed by
Mann–Whitney U-test. Data are shown as individual measurements
and medians (***P < 0.001).
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intraperitoneal infection
PEA-treated and saline-treated mice were sacrificed 24
hours after ip infection. The bacterial concentration in
blood of PEA-treated mice was 2.8 × 109 (5.6 × 107/6.7 ×
109 CFU/ml) compared to 1.6 × 1010 (1 × 109/9.9 × 1010
CFU/ml) in saline-treated mice (P = 0.013; Mann–Whit-
ney U-test) (Figure 6a). Bacterial concentrations in the
spleens of PEA-treated mice were 4 × 107 (1.7 × 107/
7.2 × 107 CFU/ml) compared to 8 × 108 (1.1 × 108/1.1 ×
109 CFU/ml) in saline-treated mice (P = 0.0005; Mann–
Whitney U-test) (Figure 6b).
Cytokine and chemokine measurement
In vitro, PEA-mediated stimulation did not induce the re-
lease of proinflammatory compounds by peritoneal macro-
phages (Figure 7). TNFα or CXCL1 levels were comparable
between unstimulated (DMSO group) and PEA-stimulatedcells. Macrophage stimulation by LPS induced the release
of 2,822 (1,564/3,027) pg/ml and 4,497 (3,939/8,742 pg/ml)





























































Figure 6 Bacterial concentrations in blood and spleen after
intraperitoneal infection. Bacterial concentrations (CFU/ml) in
blood (a) and spleen (b) 24 hours after intraperitoneal E. coli
infection. Statistical analysis was performed by Mann–Whitney
U-test. Data are shown as individual measurements and medians








































































Figure 7 Cytokine and chemokine release of palmitoylethanolamide
(PEA)- and lipopolysaccharide (LPS)-stimulated microglial
cells. TNFα (a) and CXCL1 (b) concentrations (in pg/ml) in the
supernatants of microglial cell cultures after stimulation with
different concentrations of PEA for 30 minutes and 0.01 μg/ml
LPS for 24 hours. Data are given as medians with interquartile
ranges. PEA did not stimulate the release of proinflammatory
cytokines and chemokines.
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homogenates of spleen and cerebellum 24 hours after ic
infection with E. coli K1 (Figure 8b, d, f, h). CXCL1
levels in both tissues were lower in PEA-treated than in
saline-treated mice (P = 0.0021 in cerebellum; P = 0.0095
in spleen) (Figure 8b). Pre-treatment with PEA reduced
IL-1β and IL-6 concentrations in cerebellum compared
to the levels determined in the saline-treated group (P =
0.0004 and P = 0.0001, respectively) (Figure 8d, f ). The
levels of IL-1β in spleen of PEA-treated mice were lower
than in the saline group but the differences did not
reach statistical significance. PEA- and saline-treated an-
imals showed similar amounts of IL-10 in both tissues
(Figure 8d, h).
Similarly, chemo-/cytokines were quantified 24 hours
after ip challenge with E. coli K1. In the model of systemic
infection, prophylaxis with PEA reduced the levels of IL-1β
in cerebellum homogenates (P = 0.05) (Figure 8c). CXCL1levels in cerebellum of PEA-treated mice were also lower
than those measured in saline-treated mice but the differ-
ence did not reach statistical significance (Figure 8a). The
levels of CXCL1, IL-1β and IL-6 in spleen homogenates
were similar in PEA- and saline-treated mice (Figure 8a, c,
e). PEA and saline-treated animals showed similar amounts
of IL-10 in both spleen and cerebellum homogenates
(Figure 8g).
Discussion
Sepsis and meningitis are life-threatening diseases with
a high incidence in neonates, infants and in the immu-
nocompromized and older-aged patients in which E.
coli is one of the most important pathogens [26,27].
Figure 8 Cytokine and chemokine concentrations in homogenates of spleen and cerebellum. CXCL1 (a/b), IL-1β (c/d), IL-6 (e/f),
and IL-10 (g/h) concentrations (in pg/ml) in the homogenates of spleen and cerebellum (cereb) 24 hours after intraperitoneal or intracerebral
infection with E. coli K1. Data are given as medians with interquartile ranges. Data were analyzed by Mann–Whitney U-test (*P < 0.05, **P < 0.01,
***P < 0.001).
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ceptible to sepsis and meningitis from a variety of bac-
teria and fungi. For many of these pathogens, no
vaccines are commercially available. Moreover, the ef-
fectiveness of vaccination in these patients is often re-
duced, since most vaccines are less immunogenic in
the older age group because of age-related changes in
the immune system [28].
For these reasons, infectiologists are highly interested
in epitopes shared by several serotypes of the same
species or even different species, which are suitable for
the simultaneous vaccination against multiple pathogens.
Since bacterial DNA, unlike eukaryotic DNA contains
a high rate of unmethylated cytosine-guanine (CpG)
motifs [29], recent attention has focused on this epi-
tope, which is a ligand of Toll-like receptor (TLR)-9.
Stimulation of microglial cells with CpG oligonucleo-
tides increased phagocytosis of E. coli, Streptococcus
pneumoniae and Cryptococcus neoformans and intra-
cellular killing of these pathogens by microglial cells
[30-32]. In various animal models, CpG ODN pre-
treatment conferred protection against a variety of
bloodstream and other extracerebral bacterial infections
[33-35]. Another epitope shared by many pathogens is
muramyl dipeptide (MDP), the smallest peptidoglycan con-
stituent of both Gram-positive and Gram-negative bacteria.
It is a ligand of the nucleotide-binding oligomerization
domain-like receptor 2 (NOD2), moderately activatesmicroglial cells leading to an increased phagocytosis of
bacteria and acts in an additive or synergistic way with
TLR agonists [36]. MDP is known to be an adjuvant
for vaccination, which induces antigen-specific T and B
cell responses, delayed-type hypersensitivity and anti-
body production. Thirty-five years ago, it was shown
that MDP enhances the non-specific immunity to
Klebsiella pneumoniae infections in adult and newborn
mice [37]. Parenteral MDP and two of its analogs
protected mice against Pseudomonas aeruginosa or
Candida albicans infections [38]. MDP conjugated
with the neoglycoprotein mannosyl human serum al-
bumin (mannose-HSA), in a murine model of visceral
leishmaniasis, strongly reduced splenic parasite bur-
den, whereas free MDP at a similar dose had very little
effect [39]. Prophylactic treatment with MDP pro-
tected mice against E. coli, Streptococcus pneumoniae,
Salmonella typhimurium, Salmonella enteritidis and
Toxoplasma gondii infections [40,41]. The synthetic
MDP derivate romurtide, given orally or subcutane-
ously, also enhanced the nonspecific resistance against
microbial infections in mice [42].
Prophylactic administration of TLR or NOD ligands
can lead to an unspecific inflammatory state character-
ized by the release of proinflammatory cytokines by im-
mune cells and elevated cytokine concentrations in the
systemic circulation. This may be a severe disadvantage
for an organism attempting to combat an infection,
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ciently eliminate pathogens, but can also acutely damage
host tissue or lead to chronic autoimmune diseases
[43,44]. This phenomenon is most devastating in the
CNS [45,46]. There, it probably contributes to neuronal
and axonal injury in the course of meningitis, encephalitis
and septic encephalopathy [47]. It probably also is the
pathophysiological basis of the deterioration of patients
with neurodegenerative diseases during infections. The
functional outcome of TLR-induced activation of microglia
in the CNS depends on a subtle balance between protective
and harmful effects [48-50]. For this reason, activation of
the TLR or NOD system aiming at increasing the resistance
to infections bears the risk of inducing collateral damage to
the vessels, the nervous system or other organs.
PEA, an endogenous compound found in most mam-
malian tissues, has well-known anti-inflammatory, neu-
roprotective and analgesic properties [1]. Moreover, oral
PEA pre-treatment (optimum dose 50 mg/kg/day for 12
consecutive days) increased the resistance of mice
against challenge with Shigella dysenteriae toxin and
streptolysin O, but also against intravenous infection
with live group A streptococci [23]. Unlike TLR or NOD
agonists, PEA does not induce the release of TNFα, IL-6
and CXCL1 by microglial cells [19]. It therefore cannot
be considered a mere immunostimulant, but a true im-
munomodulator [51].
PEA is known for its anti-inflammatory activity and ef-
fect on interleukins. PEA was shown to attenuate the
factors of intestinal injury during inflammation and to
inhibit proinflammatory cytokine production (TNFα, IL-
1β), adhesion molecules (ICAM-1, P-selectin) expres-
sion, and NF-κB expression [52].
Many effects of PEA have been shown to be dependent
on the peroxisome proliferator-activated receptor-α
(PPARα) [11,12]. In our study, the phagocytic rate in
PEA-stimulated macrophages was not as strongly de-
creased by the PPARα inhibitor GW6471 as in macro-
phages stimulated by the PPARα agonists fenofibrate
and palmitic acid. This suggests that the properties of
PEA do not only depend on the stimulation of PPARα.
In the present study, PEA administered ip did not only
act at the site of infection, but also protected against
injection of bacteria into the CNS. This compares well
with the protection against intravenous infection by
oral PEA administration [23]. Since the immune sys-
tem of the CNS is separated from the systemic circula-
tion by the blood–brain and blood-CSF barrier, the
CSF and by the glia limitans composed of astrocytic
foot processes and a parenchymal basement membrane
[53], our results suggest that PEA treatment influences
the immune defense of the whole organism including
the deep compartments. Early clinical trials with PEA
in the 1970s, at that time under the trade name ofImpulsin, demonstrated its potential of reducing the
incidence and severity of acute respiratory infections
[25]. Unfortunately, since then, no other studies focus-
ing on PEA as a prophylaxis or as an adjuvant therapy
in the management of infections have been published.
Concerning its safety, more than 3,600 patients have
been successfully treated with PEA, with no adverse ef-
fects reported in any of the trials [51,54].
In conclusion, PEA appears to increase the resistance
of animals and humans against bacterial infections with-
out inducing a chronic inflammatory state. Its efficacy
should be studied in immunocompromized animals and
with a broader range of pathogens. Because of the appar-
ently low rate of adverse effects, PEA is a promising
compound for a clinical trial in patients at a high risk of
developing life-threatening infections.
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